Opens. Delivers. Maintains.

Intersect ENT has developed the PROPEL™ dissolvable implant for chronic sinusitis patients undergoing sinus surgery. PROPEL is the first of a new category of products offering localized, controlled drug delivery directly to the sinus tissue. Inserted by a physician to maintain the surgical opening, the spring-like implant expands to prop open the ethmoid sinus and gradually delivers an advanced corticosteroid (mometasone furoate) with anti-inflammatory properties directly to the sinus lining as the implant dissolves.

The PROPEL system has been clinically proven to prevent obstruction of the ethmoid sinus following surgery. The result is improved post-operative outcomes, reducing the need for additional surgical procedures such as adhesion lysis and systemic steroids.